SCHEMBL25544371

SCHEMBL25544371

Cc1ccc2c(-c3ccc(F)c(C)c3)c(C3CCOCC3)c(Cl)nc2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 4/20 0.34
GRIN1 Q05586 4/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
KCNH2 Q12809 2/20 0.34
PDE2A O00408 1/20 0.34
PIK3CB P42338 1/20 0.32
PRKDC P78527 1/20 0.32
ATR Q13535 1/20 0.32
ATRIP Q8WXE1 1/20 0.32
GRM2 Q14416 2/20 0.32
DHODH Q02127 1/20 0.32
ACHE P22303 3/20 0.31
BRD4 O60885 1/20 0.31
CREBBP Q92793 1/20 0.31
MAPK1 P28482 2/20 0.31
SOS1 Q07889 1/20 0.31
BCHE P06276 2/20 0.31
GRIN2A Q12879 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544319 0.88 GRM2 (0.38) PDE2AGRM2SOS1JAK2JAK1
SCHEMBL25544956 0.82 TLR9 (0.35) PDE2AGRM2
SCHEMBL23887707 0.82 PARP14 (0.43) GRIN2BGRIN1CYP1A2CYP2C9CYP2C19
SCHEMBL25544569 0.80 PDE2A (0.35) GRIN2BGRIN1CYP1A2CYP2C9CYP2C19
SCHEMBL25544354 0.79 GRIN2B (0.41) GRIN2BGRIN1CYP1A2CYP2C9CYP2C19
SCHEMBL25544311 0.75 GRM2 (0.41) KCNH2PDE2AGRM2
SCHEMBL23884727 0.75 PDE2A (0.32) PDE2APIK3CBPRKDCATRATRIP
SCHEMBL25544329 0.74 GRM2 (0.36) GRIN2BGRIN1GRM2DHODHACHE
SCHEMBL25544957 0.72 PIK3CD (0.38) PDE2AMAPK1JAK2JAK1JAK3
SCHEMBL23895710 0.71 KCNQ3 (0.34) GRIN2BBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 GRIN2B 4413/4885GRIN1 3321/4885CYP1A2 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.